These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 22913770)

  • 61. A trial of prophylactic replacement therapy in haemophilia and Christmas disease.
    Ramsay DM; Parker AC
    J Clin Pathol; 1973 Apr; 26(4):243-7. PubMed ID: 4701794
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
    Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
    Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thirty years of haemophilia treatment in Oxford.
    Biggs R
    Br J Haematol; 1967 Jul; 13(4):452-63. PubMed ID: 6029949
    [No Abstract]   [Full Text] [Related]  

  • 67. Issues in making a therapeutic choice: recombinant and/or human-derived products.
    Aledort LM
    Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
    [No Abstract]   [Full Text] [Related]  

  • 68. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
    United Kingdom Haemophelia Centre Doctors' Organisation
    Haemophilia; 2003 Jan; 9(1):1-23. PubMed ID: 12558775
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
    Mancuso ME; Mannucci PM
    Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Switching patients in the age of long-acting recombinant products?
    Escobar M; Santagostino E; Mancuso ME; Coppens M; Balasa V; Taylor JA; Iorio A; Negrier C
    Expert Rev Hematol; 2019; 12(sup1):1-13. PubMed ID: 31282771
    [No Abstract]   [Full Text] [Related]  

  • 73. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Challenges for new haemophilia products from a manufacturer's perspective.
    Schulte S
    Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?: Reflections on a possible way forward.
    Keipert C; van den Berg HM; Keller-Stanislawski B; Hilger A
    Haemophilia; 2016 Sep; 22(5):647-50. PubMed ID: 27397094
    [No Abstract]   [Full Text] [Related]  

  • 79. Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
    Khawaji M; Akesson K; Berntorp E
    Haemophilia; 2009 Jan; 15(1):261-6. PubMed ID: 19149852
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.